Search results
Results From The WOW.Com Content Network
Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia. [1] It is a leukocyte growth factor. [1] It is given by subcutaneous injection. [1] The most common side effects of efbemalenograstim alfa are nausea, anemia, and thrombocytopenia. [5]
Agranulocytosis, also known as agranulosis or granulopenia, is an acute condition involving a severe and dangerous lowered white blood cell count (leukopenia, most commonly of neutrophils) and thus causing neutropenia in the circulating blood. [1]
[1] [8] The underlying mechanism involves blockage of dopamine receptors. [1] Diagnosis is based on symptoms. [2] Management includes stopping the triggering medication, rapid cooling, and starting other medications. [2] Medications used include dantrolene, bromocriptine, and diazepam. [2] The risk of death among those affected is about 10%. [4]
A systematic review from 2016 found that metamizole significantly increased the relative risk of upper gastrointestinal bleeding, by a factor of 1.4–2.7 times. [31] A study by one of the manufacturers of the drug found the risk of agranulocytosis within the first week of treatment to be a 1.1 in a million, versus 5.9 in a million for diclofenac.
Leukopenia – a deficiency of white blood cells, or leukocytes [1] Neutropenia – a type of leukopenia, with a specific deficiency in neutrophils [2] Thrombocytopenia – a deficiency of platelets; Pancytopenia – when all three types of blood cells; red blood cells, white blood cells, and platelets, are all deficient.
SCN manifests in infancy with life-threatening bacterial infections. [2] It causes severe pyogenic infections. It can be caused by autosomal dominant inheritance of the ELANE gene, autosomal recessive inheritance of the HAX1 gene. There is an increased risk of leukemia and myelodysplastic cancers.
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now.
Ofatumumab (Arzerra) has received a black box warning regarding the potential for it to cause progressive multifocal leukoencephalopathy and hepatitis B reactivation. [ 16 ] [ 23 ] Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for ...